Skip to main content
. 2023 Nov 27;18(11):e0294594. doi: 10.1371/journal.pone.0294594

Table 1. Baseline characteristics of total patients.

Total (n = 512) No metastasis (n = 329) Lymph node metastasis (n = 183) p-value
Sex
Male, n(%) 111 (21.7%) 62 (18.8%) 49 (26.8%) 0.037
Female, n(%) 401 (78.3%) 267 (81.2%) 134 (73.2%)
Age, years 47.34±12.71 49.53±11.70 43.41±13.49 <0.001
BMI, kg/m 2 24.80±3.92 24.77±3.71 24.84±4.25 0.849
Familial history of thyroid cancer, n(%) 62 (13.1%) 39 (11.9%) 23 (12.6%) 0.812
Autoimmune thyroid disease, n(%) 146 (28.5%) 101 (30.7%) 45 (24.6%) 0.172
Laboratory data
TSH, mIU/L 2.49±2.73 2.52±3.20 2.43±1.58 0.714
Free T4, pmol/L 15.46±3.55 15.53±3.44 15.33±3.74 0.530
Total T3, nmol/L 1.71±0.45 1.72±0.48 1.68±0.37 0.327
Thyroglobulin, ng/mL * 17.18±30.40 14.71±25.95 21.75±36.90 0.029
Thyroglobulin Ab positivity, n(%)§ 71 (16.1%) 53 (18.2%) 18 (12.0%) 0.093
Thyroglobulin Ab, IU/mL § 247.3±453.7 174.2±287.1 458.5±724.3 0.121

* 30 and

§ 72 data missing; Continuous variables are expressed as mean ± standard deviation, and categorical variables as numbers (percentages).

BMI, body mass index; TSH, thyroid stimulating hormone